



J. B. Chemicals & Pharmaceuticals Limited

Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, October 26, 2009: J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its unaudited financial results for the quarter ended on September 30, 2009.

The total income earned during the quarter was Rs. 174.51 crores against Rs. 213.35 crores in the same period during the previous year. The net sales for the quarter were Rs. 171.09 crores. The profit before tax and profit after tax for the quarter at Rs. 35.77 crores and Rs. 31.33 crores were lower against Rs. 45.81 crores and Rs. 38.47 crores respectively achieved in the same quarter previous year. The EPS for the quarter was Rs. 3.71 per equity share of FV of Rs. 2, against Rs. 4.56 in the same quarter last year.

The net sales and PAT for the half year ended on September 2009 were Rs. 306.28 crores and Rs. 44.46 crores respectively.

The international economic slowdown continued to affect the company's exports in the company's key markets. During the quarter, the company experienced as a result demand slow down in the company's key market of Russia and Ukraine.

The brand focused marketing strategy adopted in the domestic formulations business has yielded satisfactory results and the company remains positive for its growth in H2 as well as years to come. During the quarter, the company consciously scaled down its manufacturing operations at unit situated at Thane-Belapur road, Maharashtra, which affected the sales of bulk drugs division.

The company's cost control measures have helped contain the expenses and focused working capital management has resulted in lower interest cost. These measures are being pursued vigorously and are expected to partly mitigate the impact created by the economic slowdown.

During the quarter, the company received US FDA approval to its Abbreviated New Drug Application (ANDA) for Cetirizine Hydrochloride (anti-allergic) 5

mg. and 10 mg. Tablets, and plans to launch this product in US during early Q4 of the current year.

The current year continues to remain challenging in view of ongoing economic slowdown. The company is, however, determined to counteract the same through intensified marketing initiatives in domestic market, Russia, Ukraine and other markets, stringent cost control and enhanced efficiencies on all fronts.

The detailed financial results for the quarter ended on September 30, 2009 may be viewed on the company's website.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine, CIS countries and South Africa. The company continues to invest in growing its share in the regulated markets in USA, Europe, Australia and Brazil. JBCPL has a strong R & D set-up for development of NDDS formulations, filing of DMF's and ANDAs. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:

M.C. Mehta
Company Secretary- General Manager
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 3045 1311

-- x --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.